Key statistics dashboard for Bone Biologics Corporation (BBLG). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth.
Stock Data
| Price | $0.54 |
| Market Cap | $1M |
| Enterprise Value | -$3.1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.29 |
| Price / Book | 0.25 |
| P/S | 0.00 |
| EV/EBITDA | 1.41 |
| EV/Sales | 0.00 |
| EV/FCF | 1.16 |
| P/FCF | -0.37 |
| Earnings Yield | -299.30% |
| FCF Yield | -270.11% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -57.85% |
| Return on Assets | -65.16% |
| Return on Invested Capital | -78.01% |
| Return on Capital Employed | -78.01% |
Financial Health
| Current Ratio | 8.67 |
| Quick Ratio | 8.67 |
| Cash Ratio | 7.87 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 1.86 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -19.57 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.18 |
| Cash per share | 2.24 |
| FCF per share | -1.46 |
| Tangible Book Value per share | 2.18 |
| Dividend per share | 0.00 |
Related companies: BDRX · DHAI · GCTK · HSCS · INM · MOVE · NAOV
Explore sector: Healthcare · Biotechnology
More sections of BBLG: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks